Irbesartan Stada

Irbesartan, the active ingredient in Irbesartan Stada, is an angiotensin II receptor blocker (ARB) presented as an oral tablet for oral use. It lowers blood pressure and protects kidney function, and is used in patients with hypertension, diabetic kidney disease, or heart failure, often as part of a comprehensive cardiovascular management plan.

GNH USA supplies Irbesartan Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Irbesartan is an angiotensin II receptor blocker indicated for several cardiovascular and renal conditions.

- Hypertension: reduces systolic and diastolic blood pressure, helping patients reach target levels. - Diabetic nephropathy: slows progression of kidney damage in individuals with type 2 diabetes. - Heart failure: improves symptoms and lowers the risk of hospitalization in patients with reduced ejection fraction.

Irbesartan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Fatigue - Nausea - Diarrhea

Serious or Rare Side Effects: - Hyperkalemia - Acute kidney injury - Angioedema - Severe hypotension

When prescribing Irbesartan, clinicians should observe several safety considerations.

- Blood pressure monitoring: check for excessive hypotension after initiation or dose changes. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Serum potassium measurement: monitor for hyperkalemia, especially with concomitant potassium‑sparing agents. - Pregnancy warning: avoid use in pregnancy due to risk of fetal toxicity (Category D). - Drug interactions: review concomitant use of ACE inhibitors, aliskiren, or potassium supplements. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Irbesartan interacts with several medicines that can alter its efficacy or safety profile.

Major Interactions (Avoid): - ACE inhibitors or aliskiren in pregnancy: combined use can cause severe hypotension and fetal harm. - Potassium‑sparing diuretics (e.g., spironolactone): increase risk of hyperkalemia. - NSAIDs (e.g., ibuprofen): may reduce antihypertensive effect and impair renal function. - Lithium: increased lithium levels leading to toxicity.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: additive blood pressure lowering may require dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): may raise Irbesartan plasma concentrations. - CYP3A4 inducers (e.g., rifampin): may lower Irbesartan levels, reducing efficacy.